about
Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice GuidePI3K/Akt/mTOR inhibitors in breast cancerA phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.Evaluation of nanofluidics technology for high-throughput SNP genotyping in a clinical settingImpact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patientsPredictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population.Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort studyBrain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer.Reducing the risk of peripherally inserted central catheter line complications in the oncology setting.Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients.Whole-exome sequencing of breast cancer, malignant peripheral nerve sheath tumor and neurofibroma from a patient with neurofibromatosis type 1.Outcome after neoadjuvant chemotherapy in Asian breast cancer patients.Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.Identification of Novel Breast Cancer Risk Loci.Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients.Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.Measurement properties of the English and Chinese versions of the Functional Assessment of Cancer Therapy-Breast (FACT-B) in Asian breast cancer patients.Measurement properties of the eight-item abbreviated functional assessment of cancer therapy--breast symptom index and comparison with its 37-item parent measure.Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence.A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry.Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore.Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848.Distinct and heterogeneous trajectories of self-perceived cognitive impairment among Asian breast cancer survivors.Effects of chemotherapy and psychosocial distress on perceived cognitive disturbances in Asian breast cancer patients.Comparison of the measurement properties between a short and generic instrument, the 5-level EuroQoL Group's 5-dimension (EQ-5D-5L) questionnaire, and a longer and disease-specific instrument, the Functional Assessment of Cancer Therapy-Breast (FACTAssociation of common genetic variants with breast cancer risk and clinicopathological characteristics in a Chinese population.Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.Evaluation of three polygenic risk score models for the prediction of breast cancer risk in Singapore Chinese.Replication and Meta-analysis of the Association between BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving ChemotherapyBreast cancer risk in neurofibromatosis type 1 is a function of the type of NF1 gene mutation: a new genotype-phenotype correlationClinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go?Lymphomatous infiltration of the peripheral nervous system in enteropathy-associated T-cell lymphomaAdjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelinesEverolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trialValidation of the AJCC 8th prognostic system for breast cancer in an Asian healthcare settingBreast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotypeResponse to Sung, Rosenberg, and YangDetection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platformElucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancersLow-dose anti-inflammatory combinatorial therapy reduced cancer stem cell formation in patient-derived preclinical models for tumour relapse prevention
P50
Q26749476-8D902F8C-7B6B-4B8C-8D94-A04C290EDB26Q26771394-05AFA9E0-B208-473F-8863-5FD148CC250CQ33370514-3B98D337-F591-432A-B770-851A5FFD14CCQ34801132-68577EDD-4E4D-4EF9-8B12-DC416C335421Q34976487-45C7CFA6-9754-4B40-9D74-A4188356877CQ35722508-CE3DC50B-A416-46DA-860B-92C92140B198Q35775258-9322F293-1943-41C0-B00F-E53632E846D3Q36493824-2AE870EA-5AC3-47D3-8948-219BAA12407FQ36591647-4DE3AF57-C53E-4382-ACE3-9F17CF2DC8FEQ36924724-DB573EC1-1DFC-4098-858D-9E2BD451ECA9Q37441728-A2D0D566-26A8-4628-B638-BF7255E268EAQ37609483-0C573DA8-5C79-4C4C-9E3F-12928171164DQ38373831-4DA6AF70-DD1F-4927-9BAF-A46C00D196E0Q38642360-87E6F95D-4913-49E4-8D89-03DB4668903EQ39225496-5E6E8186-EA61-4E2F-9257-C3D37F004165Q45044547-4E6CFE4A-7B8F-4150-BA0D-85B3E03828C0Q45268899-9ABC5DEA-2747-491A-932D-0AE1F73F545CQ45838177-5D65C5B3-8A62-4056-983C-E996B9F914D1Q45964566-66BE8DFD-DCFC-467B-8060-2C87ADCF6BCEQ47104764-D2FCD24B-DCDF-4B8E-B4E9-5FE23E63F37EQ47121298-861DA149-75DE-4F9A-B59F-45208357C16FQ47182839-BE2EB16A-72A4-4A71-AD29-4F8E90274052Q48281338-F1286389-DD7E-4153-BEAC-C21E27DF2550Q48334506-44192C91-4DC3-4D56-A021-56CAD3F45F16Q48374697-E5ACC309-B58F-4F77-AAE3-56D06775544FQ51311827-CBC0B542-473F-4F3F-9ACA-DA3DD3F0A542Q54113079-F1F05984-4025-420C-AFAD-4ACB570D85CAQ55040393-C8DB3CFC-DBE9-4AB4-B245-485C2C4FC917Q58090010-85522E81-54CE-478C-ABD0-E71D4BDF6D17Q64004343-91E3285D-F45E-4545-9ABB-74F9BCCC28C0Q80018036-806B2F8E-86E7-4257-A360-66145505A612Q81603384-9E87285D-C15A-46C7-805B-9510C5A9A83CQ83877710-3B3BFE7E-E41F-40F3-AE06-2BE8BF7D576FQ87702640-8221D08E-9C3C-4DB1-9274-F302B2B5DC11Q88423247-F3ECB480-5577-4170-8E97-72F9CDFDA675Q89172153-D178D568-7AD2-4142-A9CC-BC7370A1FEB5Q90215888-3062B8CA-9726-454D-A555-2FA1752FEBB8Q90280131-DDAD4661-A740-4606-963B-144CFC9E92A6Q90652072-4D422B96-D545-4AFC-9AF4-0964012BE7C8Q91322932-73FD7835-CB30-4F34-9E6F-8F8F45F83781
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Yoon-Sim Yap
@ast
Yoon-Sim Yap
@en
Yoon-Sim Yap
@es
Yoon-Sim Yap
@nl
type
label
Yoon-Sim Yap
@ast
Yoon-Sim Yap
@en
Yoon-Sim Yap
@es
Yoon-Sim Yap
@nl
prefLabel
Yoon-Sim Yap
@ast
Yoon-Sim Yap
@en
Yoon-Sim Yap
@es
Yoon-Sim Yap
@nl
P106
P31
P496
0000-0002-0347-5066